These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 12239944)

  • 1. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.
    Flisiak R; Maxwell P; Prokopowicz D; Timms PM; Panasiuk A
    Hepatogastroenterology; 2002; 49(47):1369-72. PubMed ID: 12239944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of five serum markers for liver fibrosis].
    Luo R; Yang S; Xie J; Zhao Z; He Y; Yao J
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):148-50. PubMed ID: 11412388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis.
    Böker KH; Pehle B; Steinmetz C; Breitenstein K; Bahr M; Lichtinghagen R
    Hepatogastroenterology; 2000; 47(33):812-9. PubMed ID: 10919037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B.
    Lebensztejn DM; Sobaniec-Lotowska M; Kaczmarski M; Werpachowska I; Sienkiewicz J
    Hepatogastroenterology; 2004; 51(55):229-33. PubMed ID: 15011870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
    Castilla A; Prieto J; Fausto N
    N Engl J Med; 1991 Apr; 324(14):933-40. PubMed ID: 1900574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis.
    Flisiak R; Pytel-Krolczuk B; Prokopowicz D
    Cytokine; 2000 Jun; 12(6):677-81. PubMed ID: 10843744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The relationship between TGFbeta1 and TIMP-1 and its effects on the diagnosis of hepatic fibrosis].
    Zhang LF; Tian XX; Wang CF
    Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):258-60. PubMed ID: 17456311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
    Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
    Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?
    Vardar R; Vardar E; Demiri S; Sayhan SE; Bayol U; Yildiz C; Postaci H
    Hepatogastroenterology; 2009; 56(94-95):1459-65. PubMed ID: 19950810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biochemical markers of fibrosis in chronic hepatitis and liver cirrhosis of viral origin].
    Kozłowska J; Łoch T; Jabłońska J; Cianciara J
    Przegl Epidemiol; 2001; 55(4):451-8. PubMed ID: 11921731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relationship of serum metalloproteinase with the severity of liver fibrosis and inflammation].
    Yin SS; Li XM; Wang BE; Wang TL; Jia JD; Qian LX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):666-8. PubMed ID: 15623375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B.
    Flisiak R; Al-Kadasi H; Jaroszewicz J; Prokopowicz D; Flisiak I
    World J Gastroenterol; 2004 Sep; 10(18):2661-5. PubMed ID: 15309715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis.
    Dudás J; Kovalszky I; Gallai M; Nagy JO; Schaff Z; Knittel T; Mehde M; Neubauer K; Szalay F; Ramadori G
    Am J Clin Pathol; 2001 May; 115(5):725-35. PubMed ID: 11345837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.
    Patel K; Gordon SC; Jacobson I; Hézode C; Oh E; Smith KM; Pawlotsky JM; McHutchison JG
    J Hepatol; 2004 Dec; 41(6):935-42. PubMed ID: 15582126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
    Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
    World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of serum TGFb1 of patients with chronic hepatitis B in liver fibrosis formation].
    Liu F; Li B; Nan Y
    Zhonghua Gan Zang Bing Za Zhi; 1999 Dec; 7(4):196-8. PubMed ID: 10715784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C.
    Fujita N; Sugimoto R; Ma N; Tanaka H; Iwasa M; Kobayashi Y; Kawanishi S; Watanabe S; Kaito M; Takei Y
    J Viral Hepat; 2008 Jul; 15(7):498-507. PubMed ID: 18331251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.